Source comparison
PT-141 Benefits: Clinical vs Compounded Comparison
Vyleesi (FDA-approved bremelanotide) FDA-approved for HSDD in premenopausal women 1.75mg subcutaneous, at least 45 minutes before anticipated sexual activity $150–$200 per dose (insurance rarely covers) Pre-filled autoinjector pen Consistent potency, standardi
This comparison does not assign a generated winner or score.
- Vyleesi (FDA-approved bremelanotide)
- FDA-approved for HSDD in premenopausal women
- 1.75mg subcutaneous, at least 45 minutes before anticipated sexual activity
- $150–$200 per dose (insurance rarely covers)
- Pre-filled autoinjector pen
- Consistent potency, standardized formulation, highest cost. Best for patients prioritizing regulatory oversight
- Compounded PT-141 from 503B facilities
- Prepared under FDA-registered outsourcing facility standards, not FDA-approved as a drug product
- 1.0–1.75mg subcutaneous, researcher-determined schedule
- $15–$40 per dose depending on supplier
- Reconstituted vial with insulin syringe or supplied pre-filled syringe
- Same active molecule as Vyleesi, 70–85% cost reduction, requires reconstitution knowledge. Best for research applications or patients comfortable with self-administration
- Research-grade PT-141 peptide (lyophilized powder)
- Not for human consumption. Research use only
- Variable, determined by research protocol
- $8–$25 per dose equivalent depending on batch size
- Reconstituted with bacteriostatic water, researcher-administered
- Maximum cost efficiency, requires sterile technique and proper storage (−20°C before reconstitution, 2–8°C after), peptide purity confirmed by third-party testing. Best for institutional research or advanced users
- The practical difference between Vyleesi and compounded PT-141 is regulatory traceability and convenience. The active molecule is identical. Both are synthetic bremelanotide acetate with the same amino acid sequence. Compounded versions prepared by FDA-registered 503B facilities like those supplying PT 141 Bremelanotide follow USP standards for sterility and potency, but they do not undergo the same batch-level FDA review as branded pharmaceuticals. For patients, that means lower cost and identical mechanism of action, but with slightly less supply chain oversight.
- Research-grade lyophilized peptides are the most cost-effective option but require the user to handle reconstitution, sterile technique, and proper storage. Unreconstituted PT-141 must be stored at −20°C to prevent degradation; once reconstituted with bacteriostatic water, it remains stable at 2–8°C for 28 days. Any temperature excursion above 8°C for more than 4 hours risks protein denaturation. The peptide may appear clear and unchanged but lose pharmacological activity entirely. This is the single most common source of "PT-141 didn't work" reports we've encountered in research settings.